Table 1.
Number of events for each main outcome reported by 23 randomised trials in prevention of stroke in patients with atrial fibrillation
| Study | Study size* | Reporting pattern† | Stroke | Myocardial infarction | All-cause mortality | Bleeding | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | or SE | Ischaemic | Haemorrhagic | All | Minor | Major | IC | GI | CR | ||||||||
| ACTIVE W | 6706 | 1 | 159 | NA | 132 | 20 | 59 | 317 | 1199 | 1049 | 194 | NA | NA | NA | |||
| AF-ASA-VKA-CHINA | 101 | 2 | NA | 18 | 14 | NA | 5 | 4 | 14 | 9 | 3 | NA | 1 | ||||
| AF-DABIG-VKA-JAPAN | 166 | 2 | NA | 1 | NA | NA | NA | NA | 45 | NA | 3 | NA | NA | 14 | |||
| AF-EDOX-VKA-ASIA | 234 | 2 | NA | 0 | NA | NA | NA | NA | 57 | 48 | 2 | NA | 1 | 11 | |||
| AF-EDOX-VKA-JAPAN | 519 | 2 | NA | 1 | NA | NA | NA | NA | 115 | NA | 5 | NA | NA | 20 | |||
| AF-EDOX-VKA-MULTI | 1143 | 2 | NA | 11 | NA | NA | 5 | NA | 114 | 52 | 13 | NA | NA | 62 | |||
| AF-VKA-ASA-CHINA | 440 | 2 | 10 | NA | 9 | 1 | NA | 11 | NA | 25 | 8 | NA | 7 | NA | |||
| AFASAK | 671 | 2 | 20 | NA | NA | NA | NA | 15 | 23 | NA | NA | NA | 5 | NA | |||
| AFASAK II | 339 | 1 | 19 | 22 | 8 | 2 | 8 | 31 | NA | 68 | 9 | 3 | NA | NA | |||
| ARISTOTLE | 18140 | 3 | 449 | 477 | 337 | 118 | 192 | 1272 | 5416 | NA | 789 | 174 | 224 | 1490 | |||
| ARISTOTLE-J | 218 | 2 | NA | 3 | 1 | NA | 0 | 0 | 41 | 36 | 1 | NA | 1 | 6 | |||
| AVERROES | 5599 | 1 | 154 | 164 | 128 | 15 | 52 | 251 | NA | 341 | 83 | 24 | 26 | 263 | |||
| BAFTA | 973 | 1 | 94 | NA | NA | NA | 30 | 215 | NA | NA | 50 | NA | NA | NA | |||
| Chinese ATAFS | 704 | 2 | 23 | NA | NA | NA | NA | 12 | NA | NA | NA | NA | NA | NA | |||
| ENGAGE AF-TIMI 48 | 21 026 | 2 | 958 | 1016 | 804 | 169 | 443 | 2349 | NA | 1851 | 1196 | 234 | 551 | 4450 | |||
| EXPLORE-Xa | 508 | 2 | 2 | NA | 2 | NA | 0 | 2 | 118 | 109 | 8 | NA | NA | 18 | |||
| J-ROCKET AF | 1278 | 2 | 31 | 33 | 24 | 7 | 4 | 12 | NA | NA | NA | 15 | 18 | 262 | |||
| PATAF | 272 | 1 | 7 | NA | 7 | NA | 5 | 29 | NA | NA | NA | NA | 11 | NA | |||
| PETRO | 515 | 2 | NA | 2 | NA | NA | NA | NA | 88 | NA | 4 | NA | NA | 36 | |||
| RE-LY | 18 113 | 2 | NA | 519 | 389 | 71 | 270 | 1371 | NA | 5284 | 1162 | 150 | 435 | NA | |||
| ROCKET AF | 14 236 | 2 | 405 | 575 | 310 | NA | 227 | 458 | NA | NA | 781 | 139 | 378 | 2924 | |||
| SPAF II | 1100 | 3 | NA | 67 | 63 | NA | 34 | 127 | NA | NA | NA | 18 | NA | NA | |||
| WASPO | 75 | 2 | 0 | NA | NA | NA | NA | 3 | NA | 10 | 3 | NA | 3 | NA | |||
| Total | 93 076 | 2331 | 2909 | 2228 | 403 | 1334 | 6479 | 7230 | 8882 | 4314 | 757 | 1661 | 9556 | ||||
SE=systemic embolism; IC=intracranial; GI=gastrointestinal; CR=clinically relevant; NA=not available * Study sizes are based on the arms that were relevant to the purpose of this review. †1=Number of patients whose first event is of a given type, patients censored thereafter; 2=Number of patients experiencing at least one event of each given type; 3=Total number of events of each type.